Molecular mechanism of miRNA regulating PD-L1 expression

被引:0
|
作者
Zhao, Wenxin [1 ,2 ]
Li, Xiaolan [1 ,2 ]
Ren, Qunli [1 ,2 ]
Wang, Qian [1 ,2 ]
Liao, Chengcheng [2 ]
Ding, Tianhao [2 ]
Li, Ping [1 ]
Liu, Jianguo [2 ]
机构
[1] Zunyi Med Univ, Microbial Resources & Drug Dev Key Lab Guizhou Ter, Sch Stomatol, Zunyi 563000, Peoples R China
[2] Zunyi Med Univ, Sch Clin Med, Zunyi 563000, Peoples R China
来源
GENE REPORTS | 2023年 / 31卷
关键词
PD-L1; miRNA; Immune checkpoint; Molecular regulation; Tumor suppressor gene; BREAST-CANCER; TARGETS PD-L1;
D O I
10.1016/j.genrep.2023.101763
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
PD-L1 (programmed death-ligand 1) binding to PD-1 (programmed cell death protein 1) reduces the proliferation of PD-1-positive cells, inhibits their cytokine secretion, and induces apoptosis. miRNA (microRNA) as an important regulator of gene expression, affects the performance of gene function. Similarly, the expression of PDL1 is also regulated by miRNA. miRNAs usually negatively regulate gene expression, however, is there positive regulation? We reviewed the molecular mechanisms of the positive and negative regulation of PD-L1 expression by miRNAs. miRNAs mainly indirectly and positively regulate PD-L1 expression through the regulation of tumor suppressor genes PTEN (phosphatase and tensin homolog) and LATS2 (large tumor suppressor kinase 2), oncogene YAP1 (Yes1 associated transcriptional regulator), DNA damage response protein Ku80 (80-kilodalton subunit of the Ku heterodimer protein), etc., while negative regulation is mainly achieved by miRNAs directly binding to the 3 & PRIME;-UTR (3 & PRIME; untranslated region) of PD-L1 mRNA. And this negative regulation can also be reversed by the negative regulation of miRNAs by RNA-binding protein LIN28 (protein lin-28) or circRNAs (circular RNA) such as cire0000284 and circ-CPA4. The revealing of this mechanism provides more references and strategies for immune checkpoint therapy of tumors.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
    Ganbaatar, Otgontuya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nojima, Yutaro
    Maekawa, Naoya
    Minato, Erina
    Kobayashi, Atsushi
    Ando, Ryo
    Sasaki, Nobuya
    Miyakoshi, Daisuke
    Ichii, Osamu
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    PLOS ONE, 2020, 15 (11):
  • [42] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    LABORATORY INVESTIGATION, 2015, 95 : 123A - 123A
  • [43] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    MODERN PATHOLOGY, 2015, 28 : 123A - 123A
  • [44] PD-L1 expression in lung cancer
    Tang, Chad
    Chang, Joe Y.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (11) : 3053 - 3055
  • [45] Expression of PD-L1 in gastric cancer
    Polushkina, T.
    Sotnikova, T.
    Kalinin, D.
    Danilova, N.
    VIRCHOWS ARCHIV, 2024, 485 : S499 - S499
  • [46] PD-L1 expression in cutaneous angiosarcoma
    Harbruecker, Melissa
    Reissfelder, Christoph
    Jakob, Jens
    CHIRURGIE, 2024, 95 (09): : 766 - 767
  • [47] PD-L1 Expression in Lung Cancer
    Yu, Hui
    Boyle, Theresa A.
    Zhou, Caicun
    Rimm, David L.
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 964 - 975
  • [48] Imaging PD-L1 expression with immunoPET
    Wei, Junnian
    Evans, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [49] PD-L1 expression in cell blocks
    Erdogan-Durmus, S.
    Buyukpinarbasili, N.
    VIRCHOWS ARCHIV, 2021, 479 : S198 - S198
  • [50] PD-L1 expression in hepatocellular carcinoma
    Kanda, Hiroaki
    Mahmut, Yasin
    Shigematsu, Yasuyuki
    Sugiura, Yoshiya
    Yamamoto, Noriko
    Ishikawa, Yuichi
    CANCER SCIENCE, 2018, 109 : 1123 - 1123